Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC
Challenges of dealing with prostate cancer patients on Radium-223
PARP inhibitors: their applications and efficacy against prostate cancer
Case-based debate: is there evidence for local treatment in oligometastatic prostate cancer?
Chemotherapy for melanoma - why is it not effective and what is its future?